20.2 Severe Community-Acquired Pneumonia & Empyema

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

20.2 Severe Community-Acquired Pneumonia & Empyema

Key Takeaways Explain This Topic AI

Severe Community-Acquired Pneumonia (CAP) is defined by the ATS/IDSA criteria requiring direct ICU admission if at least 1 major criterion (invasive mechanical ventilation, septic shock requiring vasopressor therapy) OR at least 3 minor criteria (respiratory rate ≥30 breaths/min, PaO2/FiO2 ≤250, multilobar infiltrates, acute confusion, BUN ≥20 mg/dL, WBC <4,000/µL, platelets <100,000/µL, hypothermia <36°C, or hypotension requiring aggressive fluid resuscitation) are present.

Core empiric antimicrobial therapy for severe CAP in the ICU requires parenteral combination therapy: an intravenous beta-lactam (ceftriaxone 2 g daily, ampicillin-sulbactam 3 g q6h, or cefotaxime) PLUS EITHER an IV macrolide (azithromycin 500 mg daily) OR an IV respiratory fluoroquinolone (levofloxacin 750 mg daily); empirical anti-MRSA (vancomycin or linezolid) or anti-Pseudomonal (cefepime, piperacillin-tazobactam, or meropenem) coverage is reserved for patients with validated risk factors.

Diagnostic thoracentesis is mandatory for any parapneumonic effusion measuring >10 mm in depth on a lateral decubitus radiograph or ultrasound to establish whether an exudative effusion is present according to Light's criteria.

A complicated parapneumonic effusion (pleural fluid pH <7.20, glucose <40–60 mg/dL, LDH >1,000 U/L, or positive Gram stain/culture) and frank empyema (gross macroscopic pus or turbidity) mandate immediate tube thoracostomy (chest tube) drainage in addition to intravenous antibiotics to prevent fibrothorax and trapped lung.

For non-draining, multiloculated complicated parapneumonic effusions and empyemas, the landmark MIST-2 trial established that combination intrapleural therapy with tissue plasminogen activator (tPA / alteplase 10 mg) PLUS recombinant human deoxyribonuclease (DNase / dornase alfa 5 mg) administered twice daily for 3 days markedly improves drainage, slashes the need for surgical decortication by 77%, and shortens hospital stay, whereas monotherapy with either agent alone is ineffective.

Last updated: September 2026

Severe Community-Acquired Pneumonia: Clinical Stratification

Community-Acquired Pneumonia (CAP) remains the leading infectious cause of hospitalization, critical illness, and mortality in the United States. Recognizing severe CAP is essential, as delayed transfer of deteriorating ward patients to the intensive care unit (ICU) is associated with a dramatic surge in 30-day mortality.

ATS/IDSA Severity Criteria for ICU Admission

The American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) established validated severity criteria to guide direct ICU triage. Direct ICU admission is mandated if a patient meets EITHER :

At least ONE Major Criterion ; OR

At least THREE Minor Criteria .

Severity Category ATS/IDSA Criterion Clinical Significance & Threshold

Major Criteria ; (Any 1 mandates ICU) 1. Invasive Mechanical Ventilation Acute respiratory failure requiring endotracheal intubation.

2. Septic Shock Persistent hypotension requiring vasopressor therapy despite adequate volume resuscitation.

Minor Criteria ; (Any 3 mandate ICU) 1. Severe Tachypnea Respiratory rate ≥ 30 breaths/min \ge 30\text{ breaths/min} ≥ 30 breaths/min .

2. Severe Oxygenation Impairment Arterial oxygenation ratio P a O 2 / F i O 2 ≤ 250 mm Hg PaO_2/FiO_2 \le 250\text{ mm Hg} P a O 2 ​ / F i O 2 ​ ≤ 250 mm Hg .

3. Multilobar Infiltrates Radiographic involvement of ≥ 2 \ge 2 ≥ 2 anatomical pulmonary lobes.

4. Acute Confusion / Disorientation New-onset delirium or cognitive disorientation.

5. Uremia Blood urea nitrogen (BUN) ≥ 20 mg/dL \ge 20\text{ mg/dL} ≥ 20 mg/dL (or urea ≥ 7.1 mmol/L \ge 7.1\text{ mmol/L} ≥ 7.1 mmol/L ).

6. Leukopenia White blood cell (WBC) count < 4 , 000 cells/ μ L < 4,000\text{ cells/}\mu \text{L} < 4 , 000 cells/ μ L (not due to chemotherapy).

7. Thrombocytopenia Platelet count < 100 , 000 / μ L < 100,000\text{/}\mu \text{L} < 100 , 000 / μ L .

8. Core Hypothermia Core body temperature < 36.0 ∘ C < 36.0^\circ\text{C} < 36. 0 ∘ C ( 96.8 ∘ F 96.8^\circ\text{F} 96. 8 ∘ F ).

9. Hypotension Hypotension requiring aggressive intravenous fluid resuscitation.

Clinical Risk Scoring: CURB-65 vs. Pneumonia Severity Index (PSI/PORT)

Clinical decision scoring models stratify mortality and assist initial site-of-care decisions:

The CURB-65 Score

A 6-point clinical prediction tool (0 to 5 points):

C (Confusion): Acute mental status alteration (abbreviated mental test score ≤ 8 \le 8 ≤ 8 , or disorientation to person, place, or time) — 1 point

U (Uremia): Blood urea nitrogen (BUN) > 19 mg/dL > 19\text{ mg/dL} > 19 mg/dL ( > 7 mmol/L > 7\text{ mmol/L} > 7 mmol/L ) — 1 point

R (Respiratory Rate): Respiratory rate ≥ 30 breaths/min \ge 30\text{ breaths/min} ≥ 30 breaths/min — 1 point

B (Blood Pressure): Systolic blood pressure < 90 mm Hg < 90\text{ mm Hg} < 90 mm Hg OR diastolic blood pressure ≤ 60 mm Hg \le 60\text{ mm Hg} ≤ 60 mm Hg — 1 point

65 (Age): Patient age ≥ 65 years \ge 65\text{ years} ≥ 65 years — 1 point

CURB-65 Score Risk Stratification 30-Day Mortality Recommended Site of Care

0 to 1 point Low Risk 0.7 % to 2.1 % 0.7\%\text{ to }2.1\% 0.7% to 2.1% Outpatient management (oral antimicrobials)

2 points Intermediate Risk 8.0 % to 9.2 % 8.0\%\text{ to }9.2\% 8.0% to 9.2% Inpatient general medical ward admission or closely supervised outpatient monitoring

3 to 5 points High Risk 15.0 % to 30.0 % 15.0\%\text{ to }30.0\% 15.0% to 30.0% Inpatient hospital admission; evaluate for direct ICU admission if score ≥ 4 \ge 4 ≥ 4 or if ATS/IDSA criteria are met

Clinical Distinction : While CURB-65 is rapid and simple to calculate, the Pneumonia Severity Index (PSI / PORT score) is more comprehensive (incorporating 20 clinical, laboratory, and radiographic variables) and carries a superior negative predictive value for identifying low-risk candidates safely managed as outpatients.

ICU Antimicrobial Management of Severe CAP

Patients admitted to the ICU with severe CAP require immediate parenteral broad-spectrum antimicrobial therapy initiated within 1 hour of presentation , after obtaining blood cultures and respiratory secretions for microbiological analysis.

1. Standard Empiric ICU Regimen (No MRSA or Pseudomonas Risk Factors)

Standard ICU therapy requires combination parenteral therapy covering Streptococcus pneumoniae (the most common cause of fatal CAP), Legionella pneumophila , Mycoplasma pneumoniae , and Gram-negative enteric bacilli: P a r e n t e r a l β -Lactam + I n t r a v e n o u s M a c r o l i d e OR I n t r a v e n o u s R e s p i r a t o r y F l u o r o q u i n o l o n e \mathbf{Parenteral\text{ }\beta\text{-Lactam}} \quad + \quad \mathbf{Intravenous\text{ }Macrolide} \quad \text{OR} \quad \mathbf{Intravenous\text{ }Respiratory\text{ }Fluoroquinolone} Parenteral β -Lactam + Intravenous Macrolide OR Intravenous Respiratory Fluoroquinolone

Parenteral Beta-Lactam Options :

• Ceftriaxone : 2 g 2\text{ g} 2 g IV every 24 hours (preferred standard dose for severe pneumonia); OR
• Ampicillin-sulbactam (Unasyn) : 3 g 3\text{ g} 3 g IV every 6 hours; OR

Cefotaxime : 2 g 2\text{ g} 2 g IV every 8 hours.

PLUS EITHER :

Intravenous Macrolide : Azithromycin 500 mg 500\text{ mg} 500 mg IV every 24 hours. (Preferred: Extensive observational and trial data show that beta-lactam + macrolide combination yields superior survival over fluoroquinolone monotherapy in severe pneumococcal pneumonia, mediated by the immunomodulatory, anti-inflammatory suppression of cytokine release by macrolides) ; OR

Intravenous Respiratory Fluoroquinolone : Levofloxacin 750 mg 750\text{ mg} 750 mg IV every 24 hours (or Moxifloxacin 400 mg 400\text{ mg} 400 mg IV every 24 hours).

2. Risk-Stratified Coverage for MRSA and Pseudomonas aeruginosa

The 2019 ATS/IDSA guidelines abandoned the prior "Healthcare-Associated Pneumonia (HCAP)" categorization. Routine empiric broad-spectrum MRSA and Pseudomonas coverage is NO LONGER RECOMMENDED for all severe CAP admissions. Instead, empiric coverage is added strictly based on validated pathogen-specific risk factors:

Indications for Empiric Anti-MRSA Coverage :

• Prior respiratory isolation of Methicillin-Resistant Staphylococcus aureus (MRSA);
• Recent hospitalization AND receipt of parenteral antibiotics within the preceding 90 days ;

Clinical presentation of post-viral necrotizing pneumonia (e.g., severe necrotizing cavitary pneumonia following acute influenza, characterized by hemoptysis, leukopenia, and septic shock driven by Panton-Valentine leukocidin [PVL] producing MRSA strains).

Therapeutic Agents :

Vancomycin : 15 to 20 mg/kg 15\text{ to }20\text{ mg/kg} 15 to 20 mg/kg IV every 8 to 12 hours, targeting an AUC/MIC ratio of 400 to 600 400\text{ to }600 400 to 600 (or trough concentration 15 to 20 mcg/mL 15\text{ to }20\text{ mcg/mL} 15 to 20 mcg/mL ); OR

Linezolid : 600 mg 600\text{ mg} 600 mg IV every 12 hours. (Linezolid is clinically preferred in suspected toxin-producing PVL necrotizing staphylococcal pneumonia because it inhibits ribosomal protein synthesis, halting bacterial exotoxin production) .

Diagnostic Stewardship : Perform an MRSA nasal PCR screen on admission. The MRSA nasal PCR possesses a 96 % to 99 % 96\%\text{ to }99\% 96% to 99% negative predictive value ; if the nasal screen is negative, vancomycin or linezolid can be safely and definitively discontinued within 24 to 48 hours.

Indications for Empiric Anti-Pseudomonal Coverage :

• Prior respiratory isolation of Pseudomonas aeruginosa ;
• Recent hospitalization AND receipt of parenteral antibiotics within the preceding 90 days ;

Underlying severe structural lung disease (e.g., severe cystic fibrosis, severe bronchiectasis, or advanced COPD with frequent exacerbations requiring chronic systemic steroids and recurrent antibiotics).

Therapeutic Agents :

Cefepime : 2 g 2\text{ g} 2 g IV every 8 hours; OR

Piperacillin-tazobactam (Zosyn) : 4.5 g 4.5\text{ g} 4.5 g IV every 6 hours (administered as an extended 4-hour infusion); OR

Meropenem : 1 g 1\text{ g} 1 g IV every 8 hours.

3. Adjunctive Systemic Corticosteroids (The CAPE COD Trial)

The 2023 Community-Acquired Pneumonia: Evaluation of Corticosteroids (CAPE COD) multicenter double-blind randomized trial evaluated early adjunctive corticosteroid therapy in adults admitted to the ICU with severe CAP:

Intervention : Intravenous Hydrocortisone ( 200 mg/day 200\text{ mg/day} 200 mg/day continuous infusion or 50 mg 50\text{ mg} 50 mg IV every 6 hours for 4 to 8 days, followed by a taper).

Findings : Hydrocortisone significantly reduced 28-day all-cause mortality from 11.9 % 11.9\% 11.9% in the placebo group to 6.2 % 6.2\% 6.2% in the hydrocortisone group ( p = 0.006 p = 0.006 p = 0.006 ), representing an absolute risk reduction of 5.7 % 5.7\% 5.7% (number needed to treat [NNT] = 18). Furthermore, it reduced the rate of invasive mechanical ventilation and vasopressor requirements without increasing secondary nosocomial infections.

Guideline Integration : Early IV hydrocortisone is now strongly recommended in adults admitted to the ICU with severe CAP who have systemic inflammation and no contraindications.

Parapneumonic Effusion & Pleural Empyema

A parapneumonic effusion is any pleural effusion associated with bacterial pneumonia, lung abscess, or bronchiectasis, occurring in 20 % to 40 % 20\%\text{ to }40\% 20% to 40% of hospitalized pneumonia patients.

Diagnostic Thoracentesis Indication

The 10-mm Rule : A diagnostic thoracentesis must be performed promptly for any parapneumonic effusion measuring > 10 mm > 10\text{ mm} > 10 mm (or > 1 cm > 1\text{ cm} > 1 cm ) in depth on a lateral decubitus chest radiograph or bedside thoracic ultrasound.

Effusions < 10 mm < 10\text{ mm} < 10 mm are statistically unlikely to yield adequate diagnostic fluid and usually resolve with systemic antibiotic therapy alone.

Light's Criteria for Exudative Pleural Effusion

Light's criteria are the gold standard for differentiating an exudate (reflecting local pleural inflammation or increased vascular permeability) from a transudate (reflecting systemic imbalance of hydrostatic or oncotic pressure, such as heart failure or cirrhosis): An effusion is classified as an E X U D A T E if it meets ≥ 1 of the following 3 criteria: \text{An effusion is classified as an } \mathbf{EXUDATE} \text{ if it meets } \mathbf{\ge 1} \text{ of the following 3 criteria:} An effusion is classified as an EXUDATE if it meets ≥ 1 of the following 3 criteria:

• Pleural fluid protein / Serum protein ratio > 0.5 > 0.5 > 0.5
• Pleural fluid LDH / Serum LDH ratio > 0.6 > 0.6 > 0.6

Pleural fluid LDH > 2 3 > \frac{2}{3} > 3 2 ​ the institutional upper limit of normal (ULN) serum LDH (typically > 160 to 200 U/L > 160\text{ to }200\text{ U/L} > 160 to 200 U/L )

Staging and Management of Parapneumonic Effusions PARAPNEUMONIC EFFUSION STAGING SPECTRUM

• ┌─────────────────────────────────────────────────────────────────────────────────┐
• │ STAGE 1: SIMPLE (UNCOMPLICATED) PARAPNEUMONIC EFFUSION │
• ├─────────────────────────────────────────────────────────────────────────────────┤
• │ • Pathophysiology: Sterile inflammatory exudate; intact mesothelial barrier │
• │ • Fluid Analysis: Clear/serous, pH >7.20, Glucose >60 mg/dL, LDH <1000 U/L │
• │ • Microbiology: Gram stain and bacterial cultures are NEGATIVE │
• │ • MANAGEMENT: Systemic IV antibiotics ALONE; NO chest tube drainage required │
• └───────────────────────────────────────┬─────────────────────────────────────────┘
• │ Bacterial invasion of pleural space
• │ Neutrophil glycolysis & lactic acid
• ▼
• ┌─────────────────────────────────────────────────────────────────────────────────┐
• │ STAGE 2: COMPLICATED PARAPNEUMONIC EFFUSION (Fibrinopurulent) │
• ├─────────────────────────────────────────────────────────────────────────────────┤
• │ • Pathophysiology: Bacterial invasion, heavy neutrophil influx, fibrin septa │
• │ • Fluid Analysis: Turbid, pH <7.20, Glucose <40-60 mg/dL, LDH >1000 U/L │
• │ • Microbiology: Gram stain / culture may be positive or sterile │
• │ • MANAGEMENT: MANDATORY IMMEDIATE TUBE THORACOSTOMY (CHEST TUBE) DRAINAGE │
• └───────────────────────────────────────┬─────────────────────────────────────────┘
• │ Dense organization, thick fibrin peel,
• │ non-draining loculations
• ▼
• ┌─────────────────────────────────────────────────────────────────────────────────┐
• │ STAGE 3: FRANK EMPYEMA (Organizing Stage) │
• ├─────────────────────────────────────────────────────────────────────────────────┤
• │ • Pathophysiology: Frank macroscopic pus, thick gelatinous peel, trapped lung │
• │ • Fluid Analysis: Frank pus, turbid white/yellow, pH <7.00, Glucose <20 mg/dL │
• │ • Microbiology: Frank pus or Gram stain / bacterial culture POSITIVE │
• │ • MANAGEMENT: MANDATORY IMMEDIATE CHEST TUBE DRAINAGE │
• │ + Intrapleural tPA/DNase (MIST-2) for loculations vs VATS Decortication │
• └─────────────────────────────────────────────────────────────────────────────────┘
• Diagnostic Criteria Summary Table

Effusion Stage Macroscopic Appearance Pleural Fluid pH Pleural Fluid Glucose Pleural Fluid LDH Gram Stain / Culture Mandatory Drainage Required?

Simple (Uncomplicated) Clear, yellow, serous > 7.20 > 7.20 > 7.20 > 60 mg/dL > 60\text{ mg/dL} > 60 mg/dL < 1 , 000 U/L < 1,000\text{ U/L} < 1 , 000 U/L Negative NO (Resolves with IV antibiotics alone)

Complicated Cloudy, turbid, hazy < 7.20 < 7.20 < 7.20 < 40 to 60 mg/dL < 40\text{ to }60\text{ mg/dL} < 40 to 60 mg/dL > 1 , 000 U/L > 1,000\text{ U/L} > 1 , 000 U/L Positive or Negative YES ( Mandatory prompt chest tube )

Empyema Frank pus / thick turbid Typically < 7.00 < 7.00 < 7.00 Typically < 20 to 40 mg/dL < 20\text{ to }40\text{ mg/dL} < 20 to 40 mg/dL > 1 , 000 to 5 , 000 U/L > 1,000\text{ to }5,000\text{ U/L} > 1 , 000 to 5 , 000 U/L Positive (or frank pus) YES ( Mandatory urgent chest tube )

Pathophysiologic Pearl : The dramatic decline in pleural fluid pH ( < 7.20 < 7.20 < 7.20 ) and glucose ( < 40 mg/dL < 40\text{ mg/dL} < 40 mg/dL ) in complicated effusions and empyema is driven by accelerated anaerobic glycolysis by activated neutrophils and proliferating pleural bacteria, which generate high concentrations of lactic acid and consume available glucose. A pleural pH < 7.20 < 7.20 < 7.20 is the single most powerful and sensitive predictor of failure with antibiotics alone.

Intrapleural Fibrinolytic & Deoxyribonuclease (DNase) Therapy: The MIST-2 Trial

When a complicated parapneumonic effusion or empyema develops multiple fibrinous septations, dense loculations, or fails to evacuate completely through a correctly positioned chest tube:

The Failure of Monotherapy (The MIST-1 Trial) :

The initial MIST-1 trial established that intrapleural streptokinase monotherapy conferred zero clinical benefit (no reduction in mortality or need for surgery) and caused adverse bleeding events.

The Synergistic Solution: Combination tPA + DNase (The MIST-2 Trial) :

The landmark Second Multicenter Intrapleural Sepsis Trial (MIST-2) demonstrated that the combination of recombinant tissue plasminogen activator (tPA / alteplase) and recombinant human deoxyribonuclease (DNase / dornase alfa) produces dramatic therapeutic synergy:

tPA ( 10 mg 10\text{ mg} 10 mg ) breaks down dense fibrin strands and intrapleural loculations.

DNase ( 5 mg 5\text{ mg} 5 mg ) enzymaticly cleaves free extracellular DNA released by degenerating, necrotic neutrophils, which is the primary molecular factor responsible for extreme pus viscosity.

The Evidence-Based MIST-2 Protocol

Dosing Schedule :

tPA ( 10 mg 10\text{ mg} 10 mg ) dissolved in 50 mL 50\text{ mL} 50 mL normal saline instilled into the chest tube;

Followed immediately by DNase ( 5 mg 5\text{ mg} 5 mg ) dissolved in 50 mL 50\text{ mL} 50 mL normal saline instilled into the chest tube;

The chest tube is clamped for 1 to 2 hours to allow intrapleural dwell and enzymatic cleavage, then reconnected to − 20 cm H 2 O -20\text{ cm }H_2O − 20 cm H 2 ​ O suction;

Administered twice daily for 3 consecutive days (total 6 doses) .

Trial Outcomes :

77 % 77\% 77% Reduction in Surgical Intervention : Reduced referral for surgical decortication from 16 % 16\% 16% to 4 % 4\% 4% (odds ratio 0.17 0.17 0.17 , p = 0.005 p = 0.005 p = 0.005 ).

Marked Radiographic Clearance : Significant reduction in radiographic pleural opacities (mean change − 29.5 % -29.5\% − 29.5% vs − 17.2 % -17.2\% − 17.2% with placebo, p < 0.001 p < 0.001 p < 0.001 ).

Decreased Hospital Stay : Shortened median length of hospital stay by 6.7 days 6.7\text{ days} 6.7 days ( p = 0.003 p = 0.003 p = 0.003 ).

Monotherapy Failure : The trial proved that tPA alone or DNase alone showed no significant reduction in surgical referral or hospital length of stay compared to placebo.

Indications for Surgical Intervention (VATS Decortication)

Video-Assisted Thoracoscopic Surgery (VATS) decortication is indicated if:

Intrapleural tPA/DNase therapy fails to achieve adequate pleural clearance and clinical sepsis persists after 72 hours (6 doses);

Thick fibrous pleural peel forms, producing a "trapped lung" that prevents normal pulmonary re-expansion;

Presence of bronchopleural fistula or massive multi-compartment chronic organizing empyema.

Loading diagram... Severe CAP Triage & Pleural Effusion Management Algorithm